Abstract:Introduction: The global healthcare burden of COVID-19 pandemic has been unprecedented with a high mortality. Metabolomics, a powerful technique, has been increasingly utilized to study the host response to infections and to understand the progression of multi-system disorders such as COVID-19. Analysis of the host metabolites in response to SARS-CoV-2 infection can provide a snapshot of the endogenous metabolic landscape of the host and its role in shaping the interaction with SARS-CoV-2. Disease severity and consequently the clinical outcomes may be associated with a metabolic imbalance related to amino acids, lipids, and energy-generating pathways. Hence, the host metabolome can help predict potential clinical risks and outcomes. Methods: In this prospective study, using a targeted metabolomics approach, we studied the metabolic signature in 154 COVID-19 patients (males=138, age range 48-69 yrs) and related it to disease severity and mortality. Blood plasma concentrations of metabolites were quantified through LC-MS using MxP Quant 500 kit, which has a coverage of 630 metabolites from 26 biochemical classes including distinct classes of lipids and small organic molecules. We then employed Kaplan-Meier survival analysis to investigate the correlation between various metabolic markers, disease severity and patient outcomes. Results: A comparison of survival outcomes between individuals with high levels of various metabolites (amino acids, tryptophan, kynurenine, serotonin, creatine, SDMA, ADMA, 1-MH and carnitine palmitoyltransferase 1 and 2 enzymes) and those with low levels revealed statistically significant differences in survival outcomes. We further used four key metabolic markers (tryptophan, kynurenine, asymmetric dimethylarginine, and 1-Methylhistidine) to develop a COVID-19 mortality risk model through the application of multiple machine-learning methods. Conclusions: Metabolomics analysis revealed distinct metabolic signatures among different severity groups, reflecting discernible alterations in amino acid levels and perturbations in tryptophan metabolism. Notably, critical patients exhibited higher levels of short chain acylcarnitines, concomitant with higher concentrations of SDMA, ADMA, and 1-MH in severe cases and non-survivors. Conversely, levels of 3-methylhistidine were lower in this context.

Mass Spectrometry-Based Metabolomics Reveals a Salivary Signature for Low-Severity COVID-19

Molecular fingerprint by omics-based approaches in saliva from patients affected by SARS-CoV-2 infection

Composition of saliva metabolome is significantly associated with SARS-CoV2 infection and with severity of COVID-19 disease

Salivary Metabolomics in Patients with Long COVID-19 Infection

Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts

Differential expression of biomarkers in saliva related to SARS-CoV-2 infection in patients with mild, moderate and severe COVID-19

Optimization and Standardization of Human Saliva Collection for MALDI-TOF MS

ATR-FTIR spectrum analysis of saliva samples from COVID-19 positive patients

The Serum Metabolome of COVID-19 Patients is Distinctive and Predictive

MALDI(+) FT-ICR Mass Spectrometry (MS) Combined with Machine Learning toward Saliva-Based Diagnostic Screening for COVID-19

Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment

Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study

Metabolic predictors of COVID-19 mortality and severity: a survival analysis

Salivary biomarkers as pioneering indicators for diagnosis and severity stratification of pediatric long COVID

Proteomic snapshot of saliva samples predicts new pathways implicated in SARS-CoV-2 pathogenesis

Systematic Discovery and Pathway Analyses of Metabolic Disturbance in COVID-19

Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19

Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate

Profiling of Oral Microbiota and Cytokines in COVID-19 Patients